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The maintenance of B cell homeostasis requires a tight control of B cell generation,
survival, activation, and maturation. In lymphocytes upon activation, increased sensitivity
to apoptotic signals helps controlling differentiation and proliferation. The death receptor
Fas is important in this context because genetic Fas mutations in humans lead to
an autoimmune lymphoproliferative syndrome that is similar to lymphoproliferation
observed in Fas-deficient mice. In contrast, the physiological role of TNF-related
apoptosis-inducing ligand receptors (TRAIL-Rs) in humans has been poorly studied so
far. Indeed, most studies have focused on tumor cell lines and on mouse models whose
results are difficult to transpose to primary human B cells. In the present work, the
expression of apoptosis-inducing TRAIL-R1 and TRAIL-R2 and of the decoy receptors
TRAIL-R3 and TRAIL-R4 was systematically studied in all developmental stages of
peripheral B cells isolated from the blood and secondary lymphoid organs. Expression
of TRAIL-Rs is modulated along development, with highest levels observed in germinal
center B cells. In addition, T-dependent and T-independent signals elicited induction of
TRAIL-Rs with distinct kinetics, which differed among B cell subpopulations: switched
memory cells rapidly upregulated TRAIL-R1 and -2 upon activation while naïve B cells
only reached similar expression levels at later time points in culture. Increased expression
of TRAIL-R1 and -2 coincided with a caspase-3-dependent sensitivity to TRAIL-induced
apoptosis in activated B cells but not in freshly isolated resting B cells. Finally, both
TRAIL-R1 and TRAIL-R2 could signal actively and both contributed to TRAIL-induced
apoptosis. In conclusion, this study provides a systematic analysis of the expression of
TRAIL-Rs in human primary B cells and of their capacity to signal and induce apoptosis.
Staniek et al. TRAIL-Receptors in Human B Lymphocytes
This dataset forms a basis to further study and understand the dysregulation of TRAIL-Rs
and TRAIL expression observed in autoimmune diseases. Additionally, it will be important
to foresee potential bystander immunomodulation when TRAIL-R agonists are used in
cancer treatment.
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INTRODUCTION
The homeostasis of humoral immunity requires a tight control of
generation, survival, activation andmaturation of B lymphocytes.
Therefore, pro-survival and pro-apoptotic signals play a very
important role in shaping the B cell repertoire and the long-term
memory compartment. Activation-induced cell death (AICD) is
a key mechanism in the control of cell expansion and selection
in the germinal center (GC), where B cells are activated and
change their affinity for the antigen via somatic hypermutation
(1). B cells with reduced specificity or with self-reactive B cell
receptors should be eliminated (2, 3). Several members of the
tumor necrosis factor (TNF) receptor superfamily have been
implicated in the control of B cell homeostasis. Among these, Fas
(CD95, Apo-1) is involved in the control of B cell activation and
GC selection (4). Mutations in Fas lead to lymphoproliferation of
B and T cells, and to autoimmunity (5, 6).
TNF-related apoptosis-inducing ligand receptor (TRAIL-R)
1 (aka DR4 or TNFRSF10A) and TRAIL-R2 (aka DR5 or
TNFRSF10B) (7, 8) bind TRAIL and recruit downstream adaptor
proteins via a conserved motif in the intracellular domain
named death domain (DD), resulting in apoptosis. The system
is regulated by 2 membrane bound decoy receptors: TRAIL-
R3 (aka DCR1 or TNFRSF10C) and TRAIL-R4 (aka DCR2
or TNFRSF10D), that are devoid of a cytoplasmic tail or
carry a truncated intracellular DD, respectively, and block
TRAIL-mediated apoptosis (9–11). Also, the soluble TRAIL
receptor osteoprotegerin (OPG or TNFRSF11B) can inhibit
TRAIL-induced apoptosis (12) by modulating ligand availability.
Furthermore, TRAIL-Rs may form heterodimers with each
other or with other members of the TNF receptor superfamily,
resulting in modulation of signaling responses (13–15).
Most of our knowledge on TRAIL-Rs expression and function
derives from human cancer cell lines and mouse models. Mice
express only one apoptosis inducing TRAIL-R (mTRAIL-R2)
which is homologous to human TRAIL-R1 and -R2 (16)
and two decoy receptors mDcTRAIL-R1 and mDcTRAIL-R2
along with OPG (17). Mouse mDcTRAIL-R1 and -R2 differ
significantly in their amino acid sequence from their human
counterparts and are devoid of any apoptotic or non-apoptotic
signaling ability (17). Both, TRAIL and TRAIL-R deficient
mice present a normally developed immune system. However,
TRAIL-R deficient mice are characterized by dysregulated
cytokine responses of innate immune cells (18). Furthermore,
TRAIL and TRAIL-R deficient animals are more prone to
tumor development (19, 20) and TRAIL deficient mice are
more susceptible to induced autoimmunity (21). In Fas ligand
(FasL) deficient mice, knockout of TRAIL exacerbates the FasL
knockout phenotype, leading to extreme lymphoproliferation
and fatal autoimmune thrombocytopenia (22), indicating that the
TRAIL-R system partially functions as gatekeeper in absence of
Fas signaling. As the number of receptors and the structure of
decoy receptors are different, not all aspects of TRAIL-R biology
can be transferred from mouse models to the more complex
human system. In humans, TRAIL expression was described
on various different innate and adaptive immune cell types
including monocytes, macrophages, natural killer (NK) cells, T
cells and B cells (23–26). TRAIL-R expression has been described
in central and peripheral T cells and naïve and memory B
cells upon activation (27, 28). While several non-transformed
human cell types express TRAIL-Rs, many are refractory to
the pro-apoptotic function of the ligand. Nevertheless, it has
been shown that non-transformed cells can be sensitized to
TRAIL-induced apoptosis by activating cues or viral infections
(29–31). However, the results were depending on activation
protocols and specific cellular subsets, leading to inconsistent
conclusions (27, 28, 32, 33). A systematic description of TRAIL-
Rs in human B cell subpopulations is missing, as well as a
comprehensive analysis of the sensitivity of primary human B
cells to TRAIL-induced apoptosis ex vivo and upon activation.
Furthermore, the contribution of TRAIL-R1 and TRAIL-R2 to
TRAIL-induced apoptosis in human B cells is largely unknown.
Here, we provide a detailed expression profile of all TRAIL-Rs
in primary human B cells derived from peripheral blood and
secondary lymphoid organs. We show that GC B cells express
significant levels of TRAIL-Rs and that different activation signals
induced expression of all receptors accompanied by increased
susceptibility to TRAIL-induced apoptosis. Furthermore, we
show that in primary human B cells both TRAIL-R1 and
TRAIL-R2 contribute to induction of apoptosis in a caspase-3-
dependent manner.
MATERIALS AND METHODS
Human Material
Buffy coats were purchased from the blood bank of the University
Medical Center Freiburg (approval of the University Freiburg
Ethics Committee: 147/15). Tonsillar cells from secondary
lymphoid organs were obtained from biopsies of subjects without
known immunodeficiency undergoing tonsillectomy (approval
of the University Freiburg Ethics Committee: 121/11) and
providing informed consent.
Cell Isolation
PBMCs were isolated by density gradient centrifugation from
buffy coats. B cells were isolated with the EasySepTM HumanB cell
Isolation Kit (Stemcell Technologies) following manufacturers’
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instructions. Mononuclear cells were isolated from tonsillar
specimens by mechanical disruption. Minced tissue was pressed
through a 380µm meshed sieve and subsequently the cell
suspension was filtered.
Cell Culture
Magnetically isolated B cells at the concentration of 2.5–
5 × 105/mL were stimulated with CD40L and IL-21 as
described (34), or with CpG ODN 2006 (Apara Biosciences,
Germany) in Iscove’s Modified Dulbecco’s Medium (IMDM;
ThermoFisher Scientific) supplemented with 10% FCS, insulin,
apo-transferrin, non-essential amino acids, glutamine and
glutathione as described earlier (35). TRAIL (SuperKillerTRAIL,
Enzo Life Sciences), Fc-hFasL made as described (36),
TRAIL-R1 blocking antibody (MA1-19025, clone DR-4-02,
ThermoFisher Scientific), poly-caspase inhibitor Q-VD (R&D
Systems), and Staurosporine (Sigma-Aldrich) were added at
indicated concentrations.
The human Burkitt lymphoma cell line BJAB (purchased
from Leibniz-Institut DSMZ—Deutsche Sammlung von
Mikroorganismen und Zellkulturen GmbH) was cultured in
IMDM supplemented with 10% FCS.
Flow Cytometry
Phenotype of human PBMCs and B cells was determined
by flow cytometry with the following antibodies: CD16 PE
(clone 3G8), mouse IgG1 PE isotype control (clone 678.1Mc7,
all Beckman Coulter), IgD PE (polyclonal, Southern Biotech),
CD95 PE (clone DX2), CD64 FITC (clone 10.1) CD19 PE-Cy7
(clone SJ25C1, all BD), CD19 APC-H7, CD19 BV421, CD19
BV510 (all clone HIB19), CD27 PE-Cy7 (clone M-T271), CD27
PerCP-Cy5.5 (clone O323), CD38 PE-Cy7 (clone HB-7), IgD
PE-Cy7 (clone IA6-2), CD32 PE-Cy7 (clone FUN-2), mouse
IgG1 APC isotype control (clone MOPC-21), TRAIL-R1 PE
(307206, clone DJR1), TRAIL-R2 APC [307408, clone DJR2-
4 (7–8)], TRAIL-R3 PE (307006, clone DJR3, all Biolegend)
and TRAIL-R4 PE (A15779, clone TRAIL-R4-01, ThermoFisher
Scientific). Dead cell exclusion was performed by 4′,6-diamidino-
2-phenylindole (DAPI) staining or by Zombie NIR/ Aqua
Fixable Viability Kit (both Biolegend). In some experiments
cells were treated with Fc Receptor Blocking reagent (NB309;
Innovex) according to manufacturers’ instructions prior to
surface staining to control for non-specific binding of antibodies
to Fc receptors expressed on leukocytes. In blood derived
samples we identified the following B cell subpopulations among
the CD19+ alive single cell lymphocytes: Naïve B cells were
defined as CD27−IgD+, marginal zone (MZ) B cells were
defined as CD27+IgD+ and switched memory (SM) B cells
were defined as CD27+IgD− (Figure S1A, Figure 1A). Tonsillar
CD19+live B cells can be categorized into follicular (FO) B
cells, identified as CD38−IgD+ cells, SM-like B cells, defined
as CD38−IgD− and germinal center (GC) B cells, defined
as CD38+IgD− (Figure S1D, Figure 1D). Among GC B cells
dark zone (DZ) B cells can be identified as CD83−CXCR4+
cells and light zone (LZ) B cells as CD83−/+CXCR4− (37)
(Figure S1E). Mean fluorescence intensity (MFI) of indicated
markers was determined among total CD19/live B cells and
subpopulations. Intracellular staining was performed using the
IntraPrep Kit (Beckman Coulter) according to manufacturers’
instructions. Activity of caspase-3 was detected by staining
permeabilized B cells with an unconjugated rabbit anti-cleaved
caspase-3 (Cell Signaling Technologies) antibody followed by the
staining with a donkey anti-rabbit IgG PE antibody (Jackson
ImmunoResearch). Stained cells were acquired using a FACS
Canto II (BD Bioscience) and were analyzed with FlowJo
(TreeStar Inc.).
Generation of BJAB TRAIL-R2 Knockout
Cell Lines
BJAB TRAIL-R2 knockout (KO) cell lines were generated
by lentiviral delivery of a CRISPR-Cas9 vector system
(38). The vector system expresses the gRNA, Cas9 protein
and puromycin resistance gene. The gRNA was designed
using the tool at http://crispor.tefor.net/ (39). The gRNA
sequence used was 5′CGCGGCGACAACGAGCACAA3′
and respective oligos including adapters were cloned into
the lentiCRISPR v2 vector (Addgene plasmid #52961)
according to Zhang lab protocols (38). Successful cloning
was confirmed by sequencing lentiCRISPR v2-TRAIL-R2
constructs. To produce lentiviral particles, packaging cell line
293T (purchased from Leibniz-Institut DSMZ—Deutsche
Sammlung von Mikroorganismen und Zellkulturen GmbH)
was co-transfected with PAX2 (Addgene plasmid #12260),
pCMV-VSV-G (Addgene plasmid #8454) and lentiCRISPR
v2-TRAIL-R2 plasmids using the jetPEI reagents (Polyplus-
transfection) according to manufacturers’ recommendations.
Virus containing supernatant was harvested after 48 h and
filtered through a 0.45µm filter. For lentiviral transduction,
BJAB cells were cultured with lentivirus containing medium
supplemented with 8µg/ml polybrene (Merck) for 24 h. Medium
containing puromycin (Sigma-Aldrich) was added 72 h post-
transduction. BJAB TRAIL-R2 KO cell lines were confirmed by
flow cytometric analysis.
Apoptosis Assay
To determine apoptosis in BJAB cells, 2.5 × 105 cells/mL
were seeded and after 24 h apoptosis-inducing agents TRAIL,
Fc-hFasL, Staurosporine, and poly-caspase inhibitor Q-
VD were added at indicated concentrations. In some
experiments TRAIL-R1 mediated signaling was blocked by
pre-incubating cells with a monoclonal TRAIL-R1 blocking
antibody for 30min at indicated concentrations. After
overnight incubation, viability of cells was determined by
DAPI staining.
To determine caspase-3 activation in response to TRAIL in
activated cells, B cells were seeded at 2.5–5 × 105 cells/mL and
stimulated with CD40L and IL-21, apoptotic agents were added
at indicated concentrations every day. After 4 h, cells were fixed
and percentage of cleaved caspase-3+ cells was determined by
flow cytometry. To identify apoptotic B cells after 24 h of TRAIL
stimulation, cells were processed similarly with the exception
that cells were stained with AnnexinV FITC (eBioscience) and
DAPI according to manufacturers’ instructions. Percentages of
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FIGURE 1 | Differential expression of TRAIL-Rs in human B cell subpopulations. Expression of TRAIL-R1, TRAIL-R2, TRAIL-R3 and TRAIL-R4 was characterized
by flow cytometry in ex vivo CD19+ human B cells isolated from PBMCs (A–C) and tonsillar CD19+ cells (D–F). (A) Gating strategy to identify naïve (IgD+ CD27−),
marginal zone (MZ; IgD+ CD27+) and switched memory (SM; IgD− CD27−) cells from CD19+ live B cells. (B) Histograms show expression levels of indicated
TRAIL-Rs in naïve, MZ and SM B cells compared to respective fluorescent minus one (FMO) controls. (C) Mean fluorescence intensity (MFI) of TRAIL-Rs among
indicated B cell subsets. Each dot represents a biological replicate. (D) Gating strategy to identify follicular (FO; IgD+ CD38−), germinal center (GC; IgD− CD38+) and
switched memory-like (SM-like; IgD− CD38−) cells among CD19+ live B cells. (E) TRAIL-R expression in FO, GC and SM-like B cells compared to respective FMO
controls. (F) Quantifications of TRAIL-R expression among tonsillar B cell subpopulations depicted as MFI. Dots represent duplicates of six biological replicates. (C,F)
Dashed lines indicate averaged FMO controls. Mean values ± SD are shown. n.s., not significant; *adj.p < 0.05; **adj.p < 0.01; ***adj.p < 0.001. Statistical analysis
was performed using one-way ANOVA, followed by Tukey’s multiple comparison test where appropriate.
apoptotic cells were calculated by using the following formula:
% of apoptotic cells =
% A−D−
(
control
)
− % A−D− (COI)
% A−D−
(
control
) ∗100
where % A− D− (control) represents the percentage of
AnnexinV−DAPI− cells of control cells cultured in normal
cell culture medium and % A− D− (COI) represents the
percentage of AnnexinV−DAPI− cells cultured in the condition
of interest.
Quantitative PCR
Total RNA was isolated using TRIzol reagent (ThermoFisher
Scientific) according to manufacturers’ instructions. For cDNA
synthesis, 100 ng RNA were reverse-transcribed using random
hexamer primers (ThermoFisher Scientific) and SuperScript III
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reverse transcriptase (ThermoFisher Scientific). Quantitative
RT-PCR was performed using the TaqMan Gene Expression
Master Mix (ThermoFisher Scientific) and previously published
primer/probe sets TNFRSF10A (TRAIL-R1), TNFRSF10B
(TRAIL-R2), TNFRSF10C (TRAIL-R3) (40), TNFRSF10D
(TRAIL-R4; all ThermoFisher Scientific) (41). All reactions
were performed in duplicates and relative expression was
calculated using the 2−1Cq method with all mRNA levels
normalized to the reference gene RPLPO (Hs99999902_m1,
ThermoFisher Scientific).
Statistics
Statistical analysis was performed with GraphPad Prism
(GraphPad Software Inc.). Data are expressed as mean ± SD,
SEM, or 10–90 percentile range as indicated. Unpaired two-
tailed Student’s t-test, one-way ANOVA, and two-way ANOVA
were employed to test for statistical significance as indicated.
Differences are indicated and were considered significant
for p< 0.05.
RESULTS
TRAIL-Rs Expression Is Modulated Along
B Cell Development
While expression of CD40 and Fas has been studied extensively
(4, 42–45), the expression of TRAIL-Rs in human B cell
subpopulations has not been described in detail. We analyzed
TRAIL-R1, TRAIL-R2, TRAIL-R3, and TRAIL-R4 in blood
derived and tonsillar B cell subsets (Figure 1, Figure S1).
Circulating B cell subsets expressed low but variable levels of
all TRAIL-Rs, without significant differences between naïve,
marginal zone (MZ), and switched memory (SM) B cells
(Figures 1A–C, Figure S1A). As ex vivo expression of the
receptors was low, we performed control experiments to ensure
specific TRAIL-R antibody staining and exclude Fc receptor
mediated aspecific binding of antibodies. We analyzed TRAIL-
R expression of B cells ex vivo after Fc receptor blocking and
compared isotype to fluorescent minus one (FMO) controls
(Figures S1A,B) and observed that staining of TRAIL-Rs was
not influenced by nonspecific antibody binding. In line with
that, resting CD19+ B cells did not express high affinity Fcγ
receptor CD16 and low affinity Fcγ receptor CD64, albeit they
were positive for low affinity Fcγ receptor CD32 compared to
myeloid CD33+ cells (Figure S1C). In vivo activated GC derived
B cells were analyzed in tonsillar samples and we observed
increased expression of TRAIL-R1 and especially of TRAIL-
R2 in GC B cells compared to follicular (FO) and SM-like B
cells (Figures 1D–F, Figure S1D). Interestingly, FO and SM-
like B cells showed similar TRAIL-R1 and TRAIL-R2 expression
levels to their blood derived naïve and SM counterparts. TRAIL-
R3 was increased in GC B cells compared to FO and SM-
like B cells whereas TRAIL-R4 was very low in all tonsillar B
cell subsets, with GC B cells showing the highest expression
(Figure 1F). GC B cells can be further delineated phenotypically
and functionally into dark zone (DZ) and light zone (LZ) B
cells (37, 46) (Figure S1E). Expression of all TRAIL-Rs was
similar between DZ and LZ B cells (Figure S1F). Differential
expression of TRAIL-Rs in tonsillar B cells suggested a unique
and distinct susceptibility of different B cell subpopulations to
TRAIL. Increased expression of pro-apoptotic TRAIL-Rs in GC
B cells may suggest a role of TRAIL mediated apoptosis during
GC B cell selection.
TRAIL-Rs Expression Is Induced Upon T
Cell-Dependent and T Cell-Independent
Activation of B Cells
Sensitivity to apoptosis mediated by receptor-ligand pairs of
the TNF superfamily strongly depends on the expression
of respective receptors (45, 47). We monitored expression
levels of TRAIL-R1, TRAIL-R2, TRAIL-R3, and TRAIL-R4 in
blood derived B cells upon in vitro activation. T follicular
helper (TFH) cell-dependent stimulation with CD40L and
IL-21 strongly induced expression of TRAIL-R1, TRAIL-R2
and TRAIL-R3, while TRAIL-R4 remained mostly unchanged
(Figures 2A,B). TRAIL-Rs staining was not influenced by
unspecific antibody binding to Fc receptors (Figure S2A) and
Fcγ receptor expression (CD16, CD32, CD64) was not affected
by activation (Figure S2B). The four TRAIL receptors showed
different kinetics of expression: TRAIL-R1, TRAIL-R2, and
TRAIL-R3 showed a maximal expression at day 4, but while
TRAIL-R1 and -R2 sharply declined until day 6, TRAIL-R3
remained more stable (Figure 2B). Expression of TRAIL-R4 was
only weakly, incrementally induced until day 6 (Figure 2B). We
next performed qPCR for all TRAIL-R transcripts in isolated
CD19+ B cells in response to CD40L and IL-21 and found that all
TRAIL-R transcripts were expressed (Figure 2C). Interestingly,
transcription levels for all receptors were stable until day 3
and only increased at day 6, suggesting that the initial increase
in membrane protein expression was due to already present
intracellular reservoirs of translated protein [reviewed in (48)].
T cell-independent activation, mediated by toll-like receptor 9
(TLR9) agonist resulted in weaker, delayed, albeit more stable
expression of all TRAIL-Rs (Figure 2B). We found differences in
the induction of single TRAIL-Rs among B cell subpopulations
in response to TFH-dependent stimulation as SM B cells reached
the maximal expression of TRAIL-R2 after 2 days of stimulation,
much quicker compared to MZ and naïve B cells (Figure 2D,
Figure S2C). Naïve B cells reached the peak of expression of
TRAIL-R2 at day 4, when TRAIL-R2 on memory cells already
started to decline (Figure 2D, Figure S2C). Although TRAIL-
Rs expression upon activation was delayed in naïve B cells,
expression reached a level comparable to SM and MZ B cells
(Figure 2D), explaining the discrepancy with published data
showing a high expression of TRAIL-Rs in memory B cells
vs. naïve B cells after 2 days of activation (27). The dynamic
of TRAIL-Rs expression in B cell subpopulations in response
to TLR9 stimulation revealed a rapid increase of TRAIL-R2
in memory B cells, already visible at day 1, and a slower and
steady increase in TRAIL-R1 (Figure 2E). As expected, naïve B
cells were poorly responsive to TLR9 stimulation at early time
points of culture, resulting in an inefficient induction of TRAIL-
Rs (Figure 2E).
Frontiers in Immunology | www.frontiersin.org 5 April 2019 | Volume 10 | Article 951
Staniek et al. TRAIL-Receptors in Human B Lymphocytes
FIGURE 2 | In vitro activation induces TRAIL-R expression in human B cells. Expression of TRAIL-Rs was analyzed by flow cytometry and RT-qPCR in in vitro
activated human B cells isolated from PBMCs. (A) Representative histograms depict expression of TRAIL-Rs in CD19+ live B cells at day 0 and at day 3
after stimulation with CD40L+IL-21 compared to respective fluorescent minus one (FMO) controls. (B) Quantification of TRAIL-R expression in CD19+ live B cells
upon stimulation with CpG or CD40L+IL-21 up to day 6 of culture depicted as MFI (n ≥ 3). (C) RT-qPCR analysis of all TRAIL-R transcripts in isolated CD19+ B
cells upon stimulation with CD40L+IL-21 at day 2, 3 and 6 (n = 3). (D) TRAIL-R expression in naïve, MZ and SM B cells upon T cell-dependent (CD40L+IL-21)
activation up to day 6 of culture shown as MFI (n ≥ 3). (E) TRAIL-R expression in naïve, MZ and SM B cells upon T cell-independent (CpG) stimulation up to day 5 of
culture depicted as MFI (n ≥ 3). Mean values ± SEM (B,D,E) or ± SD (C) are shown. n, biological replicates. (B) *p < 0.05; **p < 0.01; ***p < 0.001. Statistical
analysis was done with two-tailed unpaired Student’s t-test.
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TRAIL Induces Apoptosis in Activated but
Not in Resting Primary Human B Cells
The regulation of AICD in T and B lymphocytes is crucial to
maintain peripheral immune tolerance and is mainly attributed
to Fas (4, 47, 49). Based on the observed increased expression of
TRAIL-Rs upon in vitro activation, we hypothesized that TRAIL
may contribute to AICD in human B cells. Resting B cells were
resistant to TRAIL- or FasL-induced apoptosis (Figures 3A,B).
On the contrary, in vitro CD40L and IL-21 activated B cells
became gradually susceptible to both TRAIL- and FasL-mediated
apoptosis until day 6 of culture (Figures 3C,D). The highest
percentage of apoptosis was observed between day 4 to day 6
(Figure 3D), corresponding to the highest expression of TRAIL-
R1 and TRAIL-R2 at day 4 and the still high expression of
TRAIL-R1 at day 5 and day 6 (see Figure 2B), suggesting that
TRAIL indeed may contribute to AICD in human B cells. Death
receptors of the TNF-R superfamily have been shown to employ
and recruit multiple adaptor and signaling molecules to induce
apoptosis. To identify the role of caspases in TRAIL-mediated
apoptosis in primary human B cells we analyzed up to day
6 of culture the progressive ability of TRAIL to induce the
activation of executioner caspase-3 after 4 h of TRAIL-R ligation
(Figure 3C). B cells activated with CD40L and IL-21 were more
prone to TRAIL-mediated activation of caspase-3 than resting
B cells (Figure 3E). Furthermore, caspase-3 activation increased
progressively until day 4 to day 6 of culture, in line with their
sensitivity to TRAIL-induced apoptosis (Figure 3F). Together,
these data provide evidence that T cell-dependent activation
induces expression of TRAIL-Rs in primary human B cells and
renders them susceptible to TRAIL-induced caspase-3 activation
and apoptosis. In this setting B cells were first stimulated with
CD40L and IL-21 and then, delayed in time (days 1–6), TRAIL
was added to the culture. This justifies the discrepancy with
the report of CD40L-mediated resistance to TRAIL-induced
apoptosis in human tonsillar and malignant B cells where CD40L
and TRAIL were added simultaneously to the B cells (50).
Both TRAIL-R1 and TRAIL-R2 Contribute
to Apoptosis in Primary Human B Cells and
Tumor B Cell Lines
Cell death induced by both TRAIL-R1 and TRAIL-R2 has been
implicated in the control of human B cell lymphoma, with a
specific contribution of each receptor, dependent on their relative
surface expression (51) Indeed, in line with published data
(52, 53) the human Burkitt lymphoma-derived B cell line BJAB
expressed both TRAIL-R1 and TRAIL-R2 (Figure S3A) and
was sensitive to TRAIL-mediated apoptosis (Figures 4A,B). Pre–
incubation with scalar concentrations of a TRAIL-R1 blocking
monoclonal antibody inhibited TRAIL-induced apoptosis in
BJAB cells progressively but did not fully abrogate cell death
(Figures 4A,B). Importantly, the TRAIL-R1 blocking antibody
completely inhibited TRAIL-induced killing in BJAB knockout
for TRAIL-R2 (BJAB TRAIL-R2 KO) (Figure 4B, Figure S3A).
Based on these data we confirmed that both TRAIL-R1 and
TRAIL-R2 contributed to the apoptosis control of tumor B
cell lines. Additionally, we validated the use of TRAIL-R1
blocking antibody as an appropriate reagent to study the relative
contribution of TRAIL-R1 and TRAIL-R2 to apoptosis. Next,
we assessed the contribution of TRAIL-R1 and TRAIL-R2 to
TRAIL-mediated apoptosis in primary human B cells. To this
end, we exposed B cells activated for 4 days with TFH-like cues
to TRAIL-R1 blocking antibody in combination with TRAIL
and analyzed cell death after 24 h (Figure 4C). TRAIL treatment
significantly reduced the percentage of living cells in a caspase-
dependent manner (Figure S3B). Pre-incubation with TRAIL-
R1 blocking antibody increased B cell survival upon TRAIL
incubation significantly, from 26 to 45% (Figure 4D). However,
TRAIL-R1 inhibition did not result in a complete abrogation of
cell death, as untreated cells showed 57% of survival (Figure 4D).
When TRAIL-R1 is blocked by the specific TRAIL-R1 antibody
the only receptor competent to induce apoptosis is TRAIL-R2.
The significant differences observed in TRAIL-R1 blocked cells
following TRAIL incubation (57 to 45%) indicate a contribution
of TRAIL-R2 to TRAIL-induced apoptosis in primary human
B cells. Thus, primary B cells are susceptible to apoptosis by
ligand-induced crosslinking of both TRAIL-R1 and TRAIL-
R2 (Figure 4D).
DISCUSSION
Activation-induced apoptosis is one of the key mechanisms to
control proliferation and selection of B lymphocytes (54, 55).
While the role of Fas has been addressed by several studies
in this context, the impact of the TRAIL-R system on human
B lymphocytes has been studied insufficiently. Importantly, the
knowledge we have frommousemodels can be poorly transferred
to the human system as the number of TRAIL receptors and
the structure of the decoy receptors are different in the two
species. Hence, we undertook the task to systematically describe
TRAIL-Rs expression in all developmental stages of human B
cells isolated from blood and secondary lymphoid organs from
naïve to SM B cells. We studied the sensitivity to apoptosis
in response to TRAIL, the activation of effector caspases and
the respective contribution of TRAIL-R1 and TRAIL-R2 to the
apoptosis induction in primary human B cells.
We found that the expression of TRAIL-Rs is modulated along
development, with GC B cells expressing highest levels of all
TRAIL receptors compared to all other B cell subpopulations.
Our data are in contrast with a previously published report
showing that TRAIL-R2 expression is restricted to monocytes
and TRAIL-R1 to B lymphocytes (56). This discrepancy may be
due to different assay sensitivities, employing different antibodies
to stain TRAIL-Rs, as well as to the fact that the analysis of single
subpopulations may increase the detection limit of the assay.
We used fluorescence minus one staining to assess background
intensity and to identify stained cells, also at low levels of
signal intensity, and we excluded aspecific staining due to Fc
receptor binding of staining antibodies. Indeed, peripheral B
cells show lower levels of TRAIL-R staining compared to GC B
cells, but still distinguishable from background. Moreover, we
showed that TRAIL-Rs are induced upon activation via CD40
and IL-21 receptor, with a kinetic specific to each subpopulation,
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FIGURE 3 | TRAIL induces caspase-3 activation and promotes apoptosis in activated human B cells. (A) Apoptosis of resting CD19+ B cells in response to TRAIL,
FasL or staurosporine (1µM) for 24 h was determined by Annexin V and DAPI staining and flow cytometric analysis. (B) Percentage of apoptotic resting CD19+ B
cells after incubation for 24 h with TRAIL, FasL or staurosporine was quantified by flow cytometry. The percentage of apoptotic B cells is shown, see Material and
Methods for formula. Each dot represents a biological replicate. (C) Experimental setup to analyze TRAIL-induced apoptosis and caspase-3 induction in T
cell-dependent activated B cells by flow cytometry. (D) Apoptosis was quantified after 24 h of TRAIL or FasL stimulation of activated B cells until day 6 of culture, as
described in (C). The percentage of apoptotic B cells is shown (n ≥ 6). (E) Representative flow cytometric analysis of FSC-A and cleaved caspase-3 in resting and
3-days in vitro activated CD19+ B cells after 4 h of TRAIL or FasL treatment. Numbers reflect mean percentage of cleaved caspase-3+ cells ± SEM (F) percentages
of caspase-3+ B cells after 4 h of TRAIL or FasL stimulation in activated B cells until day 6 of culture (n ≥ 3). (B,E) Mean values ± SD or SEM are shown, respectively.
(D,F) Data are expressed as 10–90 percentile.
with memory cells showing the fastest and highest expression
of TRAIL-R1 and TRAIL-R2. The ability of CD40 or B cell
receptor stimulation to induce TRAIL-R1 and TRAIL-R2 was
shown previously (27), but the expression of the receptors was
checked only 2 days after activation. We showed that naïve B
cells reached the same level of TRAIL-Rs expression as memory
B cells, only after a longer activation period. For the first time,
we showed that innate-like stimuli via TLR9 can induce TRAIL-
Rs expression in B cells with a distinct kinetic characterized
by a weaker and more sustained expression compared to TFH-
dependent activation, and a fast induction of TRAIL-R2 in
memory B cells. The determination of the expression levels of
receptors and their decoy is important for several reasons.
First, in other cellular systems it has been shown that
combinatorial receptor expression corresponded to their
susceptibility to apoptosis in response to TRAIL. Indeed, it was
shown that human resting monocytes and in vitro-differentiated
macrophages expressed substantial levels of TRAIL-R1 and
TRAIL-R2, and neutrophils TRAIL-R3. Accordingly, exclusively
monocytes and macrophages activated caspase-8 and underwent
apoptosis upon recombinant TRAIL treatment (57). In contrast
with these data, we found that B cells expressing TRAIL-R1
and TRAIL-R2 were resistant to TRAIL-induced apoptosis ex
vivo, but became sensitive upon activation, when their surface
receptor levels increased up to 10-fold.
Second, it has been reported that different members of the
TNF receptor superfamily can heteromerize, thereby modulating
their ligand induced signaling responses. In particular, in B
cells CD40-TRAIL-R2 association results in reduced CD40-
mediated NF-κB signaling (15). Hence, as CD40 expression is
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FIGURE 4 | Both TRAIL-R1 and TRAIL-R2 mediate apoptosis in primary human B cells and tumor B cell lines. (A) Experimental approach, describing the addition of
reagents to the culture to study TRAIL-induced apoptosis in BJAB cells by flow cytometry. (B) Percentages of live BJAB WT (left) and TRAIL-R2 KO (right) cells after
24h of scalar concentrations of TRAIL ± scalar concentrations of TRAIL-R1 blocking antibody (n = 3). (C) Experimental setup to analyze contribution of TRAIL-R1 and
TRAIL-R2 to TRAIL-induced apoptosis in activated B cells by flow cytometry. (D) Representative identification of live primary B cells by FSC-A and SSC-A (left) and
quantification (right) of live B cells after 24 h of TRAIL stimulation ± TRAIL-R1 blocking antibody (1µg/ml) at day 4 of culture by flow cytometry. Dots represent
triplicates of four biological replicates. (B, D) Mean values ± SD are shown. (B) n, independent experiments. (D) *adj.p < 0.05; ***adj.p < 0.001. Statistical analysis
was performed using two-way ANOVA, followed by Tukey’s multiple comparison test where appropriate.
constant along B cell development the modulation of TRAIL-R2
expression that we observed might directly result in an intrinsic
difference in response to CD40 activation in B cells.
Third, in line with the resistance of B cells to TRAIL-
induced apoptosis ex vivo, it has been reported that TRAIL
acts as an apoptosis inducer for cancer cells sparing non-
tumor cell targets. The sensitivity of tumor cells to TRAIL
is associated with the constitutive embedding of TRAIL-R1
in lipid micro domains, whereas its exclusion was associated
with TRAIL resistance. These data, derived from the study of
chronic lymphocytic leukemia, show that not only the expression
but also the location of the receptor within the membrane
controls the susceptibility to apoptosis induced by TRAIL.
Notably, the sole recruitment of TRAIL-R1 and not TRAIL-
R2 was linked to apoptosis of the cells in this study (58).
Indeed, recent studies show that the plasma membrane of
B lymphocytes is highly compartmentalized (59–61), and the
compartmentalization of the receptors changes upon activation,
contributing to modulation of signaling. Unfortunately, the
location of TRAIL-Rs within the plasma membrane in resting
and activated B cells is not known. Nevertheless, our observation
that activation of B cells renders them susceptible to TRAIL-
induced apoptosis, tempts us to hypothesize that relocation
of the TRAIL receptors may contribute to this phenomenon.
Alternatively, different oligomeric requirements may be needed
to trigger apoptotic signals in activated or resting cells as it was
shown in different tumor cell lines (62, 63).
We show that activated B cells in a T cell-dependent manner
(CD40L+IL21) are progressively sensitive to TRAIL-induced
apoptosis, which correlates with the increased expression
of TRAIL-R1 and TRAIL-R2 following activation. These
observations are opposing to the reported CD40L-mediated
resistance to TRAIL-induced apoptosis in human follicular
lymphoma B cells and normal tonsillar B cells (50). In this
study TRAIL-induced apoptosis was inhibited by concomitant
stimulation with CD40L and attributed to CD40-induced
activation of the NF-κB1 pathway. In fact, protection from
Fas or TRAIL-R mediated apoptosis by simultaneous CD40
ligation has been reported (64–66). Here, we studied TRAIL-
induced apoptosis in blood-derived B cells which received T
cell-dependent activation cues (i.e., CD40L and IL-21) at earlier
time points, which allowed us to test intrinsic responses of
B cells expressing significant levels of pro-apoptotic TRAIL-
Rs to TRAIL. Our findings are important because during GC
B selection in vivo, pro-survival signals like CD40L and IL-
21 are limiting and only transiently provided by TFH cells (46,
67). Interestingly, we found that GC B cells have the highest
expression of TRAIL-Rs among tonsillar B cells. It has been
shown that both activated T and B cells express TRAIL (68), as
well as NK cells, dendritic cells and macrophages (69). Taken
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together, these data suggest that TRAIL-induced apoptosis may
contribute to the control of B cell selection and GC homeostasis.
This hypothesis is supported by data acquired frommice carrying
double knockout for TRAIL and FasL resulting in a more
severe lymphoproliferation and accelerated thrombocytopenia
when compared to FasL knockout only animals (22). There are
no available data on the expression and function of TRAIL-
Rs in autoimmune lymphoproliferative syndrome caused by
Fas mutations. Noteworthy, mutations in caspase-10 (70) or
caspase-8 (71), both downstream of Fas and TRAIL-R signaling,
result in immune dysregulation with features of autoimmune
lymphoproliferative syndrome. Moreover, caspase-8 deficiency
(71) is associated with defects in B and T cell activation and
immunodeficiency whereas caspase-10 deficiency is associated
with susceptibility to infections (72) and arthritis (73), pointing
to a dual role of caspases in inducing both apoptotic and non-
apoptotic signaling. Indeed, the real contribution of TRAIL
and TRAIL-R expression in autoimmune disease is still unclear,
as the available data are controversial. For example, decrease
of TRAIL-R2 on CD8T cells was reported in severe aplastic
anemia (74), conversely, in rheumatoid arthritis TRAIL and
its receptors (both death and decoy) were increased in both
CD4 and CD8T cells compared to control individuals, and
the variation of TRAIL-R1 on CD8T cells correlated with the
disease activity (75). Hence, the dysregulation of TRAIL-Rs
observed in autoimmunity can point both to impaired apoptosis,
as well as to compromised non-apoptotic signaling and
lymphocytes activation.
We analyzed the contribution of TRAIL-R1 and TRAIL-R2 to
TRAIL-induced apoptosis in activated primary human B cells,
and found that both receptors are involved, with TRAIL-R1
being the major contributor. These data are important as TRAIL
specifically induces apoptosis in multiple tumor cell lines, which
motivated the clinical development of several agonists of TRAIL-
Rs, especially of TRAIL-R2. Even though, to date, recombinant
forms of TRAIL, and agonistic antibodies against TRAIL-R1
and TRAIL-R2 have failed to provide clinical benefit in cancer
patients, novel cross-linking agonistic TRAIL-R antibodies are
currently under evaluation (76, 77) and different approaches
have been undertaken to re-sensitize transformed cells to TRAIL
(31, 62, 78). It became clear that a specific agonist of TRAIL-
R1 or TRAIL-R2 will not have an effect only on tumor cells,
but also on normal cells, possibly inducing apoptosis on normal
GC activated B cells for example. We could expect that this
would have implications on B cell selection, antibody responses
to antigen and formation of memory cells and plasmablasts, to
the extent of inducing an immunodeficiency.
In conclusion, our study provides a systematic analysis of
the expression, signaling capacity and induction of apoptosis
of TRAIL-Rs in primary human B cells. The results represent
the starting point for the understanding of the dysregulation
of TRAIL-Rs and TRAIL expression observed in autoimmune
diseases. Additionally, these data are important to foresee
potential bystander immunomodulation occurring on normal
cells when TRAIL-R agonists are used in cancer treatment.
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